<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01314274</url>
  </required_header>
  <id_info>
    <org_study_id>bevacizumab HHT</org_study_id>
    <secondary_id>2009-018049-19</secondary_id>
    <nct_id>NCT01314274</nct_id>
  </id_info>
  <brief_title>Intranasal Submucosal Bevacizumab for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)</brief_title>
  <official_title>A Randomized Double Blind Placebo Controlled Trial of Intranasal Submucosal Bevacizumab in Hereditary Hemorrhagic Telangiectasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <brief_summary>
    <textblock>
      In a case series intranasal submucosal bevacizumab has been shown to reduce epistaxis in
      patients suffering from Hereditary Haemorrhagic Telangiectasia together with KTP Laser
      therapy. The aim of this study is to evaluate the effectiveness of submucosal intranasal
      bevacizumab compared to placebo in a randomized double blind trial setting.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>relative change in average daily Epistaxis VAS scores compared to baseline</measure>
    <time_frame>day 10 - 84 posttreatment</time_frame>
    <description>Daily epistaxis VAS scores are recorded in a diary. The baseline score is the average daily epistaxis VAS score 4 weeks before treatment (day -28 to 0). This score is compared to the average daily VAS score day 10-84 posttreatment. The relative change of this average score compared to baseline is the primary outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Epistaxis Severity Score HHT-ESS compared to baseline</measure>
    <time_frame>3 months post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epistaxis frequency, duration and severity compared to baseline</measure>
    <time_frame>day 10 - 84 posttreatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of emergency department visits due to epistaxis compared to baseline</measure>
    <time_frame>day 10 - 84 posttreatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lab results (ferritin values, Hb, Hct) compared to baseline</measure>
    <time_frame>day 84 posttreatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of transfusions needed compared to baseline</measure>
    <time_frame>day 10-84 posttreatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average daily epistaxis VAS scores compared to baseline among age groups and among groups with different epistaxis severity</measure>
    <time_frame>day 10-84 posttreatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>HHT</condition>
  <condition>Morbus Osler</condition>
  <condition>Epistaxis</condition>
  <arm_group>
    <arm_group_label>bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>submucosal intranasal bevacizumab on day 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% NaCl intranasal submucosal on day 0</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>100mg intranasal submucosal bevacizumab in 10ml</description>
    <arm_group_label>bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NaCl</intervention_name>
    <description>10ml of 0.9% NaCl intranasal submucosal</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed and staged HHT (Shovlin et al 2000)

          -  Age 18-80

          -  Minimum of 2 episodes of epistaxis/ week

          -  Ability and willingness to complete diary and comply with study requirements.

        Exclusion Criteria:

          -  Uncontrolled hypertension (systolic blood pressure &gt; 150mmHg, diastolic blood pressure
             &gt; 90mmHg)

          -  History of a thromboembolic event, including myocardial infarction or cerebral
             vascular accident

          -  Malignancy of the upper respiratory tract within the last year

          -  Recent (&lt;3 months) or planned surgery

          -  Proteinuria

          -  Nasal intervention (Laser or Cautery) in pretreatment phase

          -  Allergy to local anesthetic
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Universitätsklinik für HNO, Medizinische Univeristät Wien</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2011</study_first_submitted>
  <study_first_submitted_qc>March 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2011</study_first_posted>
  <last_update_submitted>August 8, 2013</last_update_submitted>
  <last_update_submitted_qc>August 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Martin Burian</investigator_full_name>
    <investigator_title>Prof. Dr. Martin Burian</investigator_title>
  </responsible_party>
  <keyword>Epistaxis</keyword>
  <keyword>Osler</keyword>
  <keyword>Weber</keyword>
  <keyword>Rendu</keyword>
  <keyword>HHT</keyword>
  <keyword>Hereditary haemorrhagic telangiectasia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telangiectasis</mesh_term>
    <mesh_term>Epistaxis</mesh_term>
    <mesh_term>Telangiectasia, Hereditary Hemorrhagic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

